Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;55(1):40-47.
doi: 10.1038/s41409-019-0547-8. Epub 2019 May 14.

Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application

Riad El Fakih  1 , Shahrukh K Hashmi  2   3 , Stephen O Ciurea  4 , Leo Luznik  5 , Robert Peter Gale  6 , Mahmoud Aljurf  7
Affiliations
Review

Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application

Riad El Fakih et al. Bone Marrow Transplant. 2020 Jan.

Abstract

The last decade had witnessed a remarkable reduction in the incidence of acute and chronic GvHD (graft versus host disease) in both related and unrelated transplants mostly due to the improved resolution of HLA (human leukocyte antigen) typing and the new methods for GvHD prevention. The use of post-transplant cyclophosphamide (PTCY) to mitigate the bidirectional alloreactivity in the setting of haploidentical transplant have revolutionized and revived the field. Based on the promising results of PTCY in the haploidentical transplant field many groups used the same strategy in the setting of HLA-matched donors. This review will carefully examine the available data about the use of PTCY in HLA-matched setting.

PubMed Disclaimer

References

    1. Storb R, Pepe M, Deeg HJ, Anasetti C, Appelbaum FR, Bensinger W, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood. 1992;80:560–1. - PubMed - DOI
    1. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880–7. - PubMed - DOI
    1. Bhatia S, Francisco L, Carter A, Sun C-L, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–92. - PubMed - PMC - DOI
    1. Weisdorf D, Zhang M-J, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 18:1727–33. - PubMed - PMC - DOI
    1. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant T. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med. 1981;304:1529–33. - PubMed - DOI

Publication types

Substances

LinkOut - more resources